Skip to main content

Table 2 The vaccine comparators and schedules used in each economic evaluation

From: Economic evaluations of vaccines in Canada: a scoping review

Vaccine

Number of studies—no vaccine

Number of studies—type of vaccine

Number of studies—vaccine programb

Funding and target populationc

Escherichia coli

1 (0/1)a

–

–

Private

Group B Streptococcus

1 (1/1)

–

–

Not yet available

Hepatitis A

–

1

–

Private

Hepatitis B

5 (3/5)

–

1

Public-universal

Hepatitis C

1 (1/1)

–

–

Not yet available

Herpes Zoster

2 (2/2)

–

–

Private

HPV

7 (7/7)

4

2

Public-universal

Influenza—(seasonal and H1N1)

6 (5/6)

1

4

Public-Universal/targeted

Measles or Mumps or MMR

2 (2/2)

–

3

Public-universal

Meningococcal A, C, Y, W135

2 (1/2)

2

1

Public-universal

Meningitis B

1 (0/1)

–

–

Public-targeted/private

Pertussis

1 (1/1)

2

2

Public-universal

Pneumococcal

4 (4/4)

4

1

Public-universal

Rabies

1 (1/1)

–

–

Private

Rotavirus

2 (2/2)

2

–

Public-universal

Tetanus

1 (1/1)

–

–

Public-universal

Varicella

3 (2/3)

–

1

Public-universal

  1. a Ratio represents the number of studies that found the vaccine was cost-effective compared to no vaccine
  2. b For example: schedule, booster dose, universal vs. targeted
  3. c Funding and target population for vaccines as of March 2015